UCB Sues KV Pharmaceutical Over Generic Metadate

Law360, New York (April 22, 2008, 12:00 AM EDT) -- Belgian pharmaceutical giant UCB Inc. has slapped KV Pharmaceutical Co. with a patent infringement suit over the generics maker's plan for a generic version of UCB's attention deficit and hyperactivity disorder treatment.

The complaint, lodged on Friday in the U.S. District Court for the District of Delaware, claims KV filed an abbreviated new drug application with the U.S. Food and Drug Administration, seeking approval to make and sell a generic version of UCB's Metadate drug.

UCB holds U.S. Patent Number 6,344,215, titled “Methylphenidate modified release formulations,”...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.